European Cancer Organisation – ECO shared on LinkedIn:
“Clinical trials have an important role in delivering best outcomes to cancer patients and systems. Yet Europe faces growing challenges in attracting cutting-edge research and translating it into meaningful progress for all.
At this year’s European Cancer Summit, our Research Policy Network is bringing together researchers, policymakers and patient advocates to discuss how Europe can strengthen its clinical trials landscape.
The priorities include:
- Streamlining regulatory pathways to accelerate clinical research and innovation.
- Strengthening cross-border collaboration and equitable access to clinical trials.
- Ensuring that Europe’s research excellence translates into practical improvements in cancer care.
These ambitions are also reflected in our recently published report proposing a European Institute that would help strengthen coordination across European cancer initiatives and support clinical research and innovation.
‘Horizon has funded partnerships and research that will transcend the Cancer Mission. It is projected that 2.3 million lives will be improved as a result.’ Joanna Drake, Deputy Director-General, DG Research and Innovation (DG RTD), European Commission.
‘Why do trials matter? They are the epicentre of new solutions and innovation. For rare cancers and rare diseases, trials are the only hope we can give patients.’ Stine Bosse MEP
Explore our vision for a European Cancer Institute.”
You can also read:
New Policy Action Report Addresses Stigma as a Barrier to Cancer Care – European Cancer Organisation